Stocks | Market Playground

Archive for the ‘Stocks’ Category

John Hussman: The Market’s ‘Dancing on the Edge of a Cliff’

Posted 14 May 2012 — by Covestor
Category Investing, Market News, Stocks, Technical Analysis, Trading

By Mick Weinstein

John Hussman

In his recent weekly commentaries, mutual fund manager John Hussman has warned that current market internals – vis-a-vis its return/risk profile – are among the worst recorded on the historical record. In this week’s commentary, Hussman finds that over the past 7 days things have become even worse, and offers a chart to illustrate (emphasis added):

The green bands in the chart below depict all of the points since 1980 in the neighborhood of present conditions – having a nearly similar prospective return/risk profile, coupled with a particularly hostile “exhaustion syndrome” that has been a hallmark of the worst market outcomes in recent decades. The blue line shows the S&P 500 Index. As I noted in Goat Rodeo, “what this combination picks up is an already fragile set of market internals that has enjoyed an ‘exhaustion rally’ that both exceeds earnings growth and is met with overbullish sentiment.” Read More

To discuss this article or any stock, please visit The Playground Discussion Forum!

Tags: chart, charts, commentary, conditions, crash, decline, Earnings, earnings growth, index, investing, John Hussman, manager, Market, market internals, markets, Mick Weinstein, mutual fund, mutual fund manager, rally, return, risk, S&P 500, S&P 500 Index, sentiment, stocks, technical analysis, trading, valuation, valuations

Doug Kass Buys JPMorgan Chase (NYSE:JPM) as an Investment

No Comments

Posted 14 May 2012 — by Covestor
Category Financial, Investing, JPM, Market News, Money Center Banks, Stocks, Trading

By Michael Tarsala

Doug Kass over at TheStreet.com says he’s buying a small amount of JPMorgan Chase & Co. (NYSE:JBM) here as an investment.

Among his arguments:

The stock is trading at a low price to book multiple, despite an ongoing share buyback.

JPM and the big banks already trade at low PE multiples (JPM is at less than a 7x forward P/E, more than a 40% discount to the S&P 500).

The cost of the $2 billion trade is fairly low to JPM, in the grand scheme of things. Read More

To discuss this article or any stock, please visit The Playground Discussion Forum!

Tags: 500, bank, big banks, buyback, discount, Doug Kass, financial, forward P/E, investing, investment, JBM, JPMorgan, JPMorgan Chase, JPMorgan Chase & Co, Michael Tarsala, multiple, NYSE, NYSE:JBM, P/E, PE multiple, price to book, price to book multiple, S&P, S&P 500, share buyback, stock, TheStreet.com, trade, trading

Why We Changed the Lineup on Our ETF Models

No Comments

Posted 14 May 2012 — by Covestor
Category Dividends, DVY, ETFs, Financial, Investing, IVV, Market News, Misc. Financial Services, Stocks, Trading, VIG

By Charles Sizemore

Charles Sizemore

Sizemore Capital is making a strategic allocation shift for all ETF portfolios with U.S. large cap exposure. This affects the Tactical ETF Portfolio and the Strategic Growth Allocation. To be consistent with Sizemore Capital’s focus on dividend growth, we are eliminating our long-term positions in the iShares S&P 500 Index ETF (NYSEARCA:IVV) and replacing them with the Vanguard Dividend Appreciation ETF (NYSEARCA:VIG).

The Vanguard Dividend Appreciation ETF (VIG) tracks the performance of the Dividend Achievers Select Index, which consists of U.S. stocks that have long history of raising their dividends. Every stock in the portfolio must have raised its dividend for a minimum of 10 consecutive years.

Much of our research and investment in recent years has focused on income and income growth, and for good reason. Capital gains can be ephemeral, and the only way that investors can realize their returns is by selling shares. Rather than enjoying the milk in the form of dividends, you end up slaughtering the cow. And continuing this analogy, once the cow is gone investors are left with nothing to eat. Read More

To discuss this article or any stock, please visit The Playground Discussion Forum!

Tags: Albert Meyer, Bastiat Capital, capital gains, cash, Charles Sizemore, companies, company, consumer, consumer sector, Dividend, Dividend Achievers Select Index, dividend yield, dividends, DVY, Earnings, ETF, ETFs, fee, fund, growth, income, income growth, index, Index Fund, indices, industrial, industrial sector, investment, investors, iShares, iShares Dow Jones Select Dividend, iShares Dow Jones Select Dividend ETF, iShares S&P 500 Index, iShares S&P 500 Index ETF, IVV, large cap, management, management fee, merger, Mergers, money, NYSEARCA, NYSEARCA:DVY, NYSEARCA:IVV, NYSEARCA:VIG, portfolio, portfolio turnover, positions, research, retirement, S&P 500, sector, sectors, shareholder, Sizemore Capital, stock, stocks, Strategic Growth Allocation, Strategy, Tactical ETF Portfolio, tax, U.S., U.S. stocks, Utilities, utilities sector, value, Vanguard Dividend Appreciation, Vanguard Dividend Appreciation ETF, VIG, yield

TomTom (AMS:TOM2) Now Offering Free Roadside Assistance

No Comments

Posted 14 May 2012 — by Lynn Shannon
Category Automotive, Consumer Electronics, Investing, Market News, Navigation, Sectors, Services, Stocks, Technology, TOM2, Trading

By Lynn Shannon

TomTom NV (AMS:TOM2) announced it will offer free roadside assistance along with its “Start” portable navigation devices (PNDs), and it will extend the offer to its VIA and GO LIVE products in the coming months.

The service provides a basic level of roadside support, including the “quick and reliable dispatches of responsible and professional service providers with a simple phone call from anywhere in the U.S,” said the company. Read More

To discuss this article or any stock, please visit The Playground Discussion Forum!

Tags: additional services, AMS:TOM2, basic, company, Cross Country Motor Club, Cross Country Perks, device, discount, dispatch, emergency, FIRE, free, free roadside assistance, GO LIVE, medical, merchants, navigation, NV, offer, option, PNDs, police, portable navigation devices, products, program, registration, repair, road service, road service professionals, roadside, roadside assistance, Roadside Assistance program, roadside support, savings, service, special deal, special deals, Start, TomTom, TomTom NV, TomTom Roadside Assistance, towing, U.S., vehicle location, VIA

Super Moon Brings Down The Financial Sector

No Comments

Posted 13 May 2012 — by Karen Starich
Category Banking, BK, CME, Economy, ETFs, Financial, Investing, Investment Services, JPM, Market News, MFGLQ, Misc. Financial Services, Money Center Banks, Regional Banks, Sectors, Stocks, Trading, XLF

Financial Sector - Super Moon - May 6th, 2012

Super Moon on May 6th, 2012

By Karen Starich

Full Moon May 6th, 2012

The distance of the full Moon on May 6th is 356,954 km from earth, which is the minimum range. If you have an opportunity to see the Moon at night you will notice the size is larger than normal. The Moon’s gravity on the earth becomes much more intense and these lunar events are called “Super Moons”, because of the increased tidal occurrences and severe weather they can produce. I should point out that the last “Super Moon” was March 19th, 2011 at a distance of 356,580 km. Read More

To discuss this article or any stock, please visit The Playground Discussion Forum!

Tags: 2012, accusations, assets, astrology, bank, Bank of New York Mellon, Bank of New York Mellon Corporation, banking, banking CEOs, banking officials, banking practices, banking scandal, BK, CEO, CEOs, clients, CME, CME Group, CME Group Inc., Corporation, Craig Donohue, credit, credit union, credit unions, criminal, criminal banking practices, crises, currency, currency swap, currency swaps, custodial bank, deposits, derivative, derivatives, Downgrade, earth, economy, ETF, Fed, Federal Reserve, financial, financial crises, financial sector, Financial Select Sector SPDR, Financial Select Sector SPDR ETF, financials, forecast, foreclosure crises, foreign currency swap, foreign currency swap transactions, full moon, future, Government, gravity, Inc., indictment, indictments, J.P. Morgan Chase, J.P. Morgan Chase & Co., Jobs, Jobs numbers, JPM, JPMorgan, JPMorgan Chase, Karen Starich, Ltd., lunar events, management, Market, market astrology, market sentiment, markets, May 6, May 6th, MF Global, MF Global Holdings, MF Global Holdings Ltd, MFGLQ, moon, mortgage, mortgage crises, mortgage foreclosure, mortgage foreclosure crises, NASDAQ, NASDAQ:CME, New York, NYSE, NYSE:BK, NYSE:JPM, NYSEARCA, NYSEARCA:XLF, officials, Pink, PINK:MFGLQ, public, questionable banking practices, retired, retirement, Robert P. Kelly, scandal, sentiment, social unrest, speculative, speculative currency swaps, super moon, supermoon, swap, swaps, The Bank of New York Mellon, The Bank of New York Mellon Corporation, The Fed, to big to fail, transactions, U.S., U.S. downgrade, union, uper Moons, weather, XLF

How to Play the Indian Growth Story: INFY, HDB, RDY

No Comments

Posted 13 May 2012 — by Covestor
Category Biotechnology and Drugs, Emerging Markets, Financial, HDB, Healthcare, India, INFY, RDY, Regional Banks, Software and Programming, Stocks, Technology, Trading

By John Linnemeier

All three of my holdings in my model are Indian ADRs. I’m in for the long haul. One of the truest things I know about the stock market is the axiom, “In the short term the market is a voting machine, and in the long term it’s a weighing machine.” I can’t say for sure how these three stocks will do in the short term, but I strongly believe that India, and most of Asia, has a bright future in the long term.

Infosys Limited (ADR) (NASDAQ:INFY) is the preeminent software exporting company in India. They are continually crawling up the value ladder with increasingly sophisticated software products. Wages for software engineers in India have increased substantially, but not enough to cut deeply into this marvelous company’s profits. Read More

To discuss this article or any stock, please visit The Playground Discussion Forum!

Tags: ADR, American, American companies, bank, clinical trials, companies, company, COST, cost savings, Dr. Reddy's, Dr. Reddy's Laboratories, Dr. Reddy's Laboratories Limited, Dr. Reddy's Laboratories Limited ADR, drugs, engineers, exporting, exporting company, generic, generic drugs, growth, HDB, HDFC Bank, HDFC Bank Limited, HDFC Bank Limited ADR, Holdings, India, India stocks, Indian, Indian ADRs, Indian growth, Indian middle class, Indian stocks, Infosys, Infosys Limited, Infosys Limited ADR, INFY, John Linnemeier, largest bank, Limited, Market, middle class, model, NASDAQ, NASDAQ:INFY, NSE, NSE:SBIN, NYSE, NYSE:HDB, NYSE:RDY, potential, private, private bank, product, products, profits, RDY, savings, SBIN, software, software engineers, software exporting, software exporting company, State Bank, State Bank of India, stock, stock market, stocks, trials, value, wages

JPMorgan Chase (NYSE:JPM) Shows Why Volcker Rule Has No Teeth

1 Comment

Posted 13 May 2012 — by Covestor
Category BAC, Banking, Bonds, Economy, Financial, Investing, JPM, Market News, Money Center Banks, Options, Sectors, Stocks, Trading

By Michael Tarsala

A $2 billion loss at J.P. Morgan Chase & Co. (NYSE:JPM) is arguably small; the bank earned more than $18 billion last year.

What’s the big deal then?

It’s a question of whether banks are still making outsized speculative market bets and now calling them hedges to satisfy the Volcker Rule. And whether we can expect even bigger “hedging” losses at other banks — and even more market volatility — in the future. Read More

To discuss this article or any stock, please visit The Playground Discussion Forum!

Tags: BAC, bank, Bank of America, Bank of America Corporation, bank stocks, banking, banking business, banks, bets, BofA, bond, broader market, broader markets, business, Chase, corporate, corporate bond, corporate bond portfolio, corporate debt, corporate debts, Corporation, correlated position, counter positions, credit, credit default swaps, credit hedge, customer facilitation, debt, debts, default, derivatives, details, executive, hedge, hedges, hedging, individual investors, institutions, investors, J.P. Morgan Chase & Co., JPM, JPMorgan, JPMorgan Chase, loss, Market, market volatility, Michael Tarsala, NYSE, NYSE:BAC, NYSE:JPM, portfolio, positions, profit, prop trading, risk, rule, Sally Krawcheck, short, shorting, speculative, speculative market bets, stakes, stocks, swaps, traders, trades, volatility, Volcker, Volcker rule

Weekly Stock Watch: SIRI, FB, JPM, C, BAC, M, JWN, JCP, SKS, TGT, PBTH, KERX, HGSI, CELH, IMSC, TROV, ARNA, VVUC, NEPH, MNKD, ACTC, CVM, AGEN, DIS, SGYP, TTNP

No Comments

Posted 13 May 2012 — by VFC's Stock House
Category ACTC, AGEN, BAC, Biotechnology and Drugs, Broadcasting and Cable TV, C, CELH, CVM, DIS, Economy, FB, Financial, Healthcare, HGSI, IMSC, Investing, IPOs, JCP, JPM, JWN, KERX, M, Market News, MNKD, Money Center Banks, NEPH, PBTH, Retail, Retail (Apparel), Retail (Department and Discount), Retail (Specialty), Sectors, Services, SGYP, SIRI, SKS, Social Networking, Stocks, TGT, Trading, TROV, TTNP, VVUV

By VFC’s Stock House

Huge trading losses at JP Morgan Chase & Co. (NYSE:JPM) that sent company shares spiraling by 10% on Friday accentuated an already lackluster trading week in the broad markets and left the door wide open for another volatile week ahead. Combine that sentiment with growing uncertainty in Europe, where recent Greek and French elections have the potential to reshape the look of austerity and other measures undertaken by European governments in an attempt to maintain control over the Euro Zone’s teetering economy, and investors may see even more of a reason to sell out and hold on the sidelines until some normalcy returns to the sinking global sentiment — a sentiment that has some predicting will bring parity between the euro and the dollar.

There could, however, be a savior in the works. Read More

To discuss this article or any stock, please visit The Playground Discussion Forum!

Tags: acquisition, ACTC, Advanced Cell Technology, Advanced Cell Technology Inc., Advisory Panel, Afrezza, Afrezza results, AGEN, Agenus, Agenus Inc, AIRSCOOTER CORP, analyst, analyst estimates, announcement, announcements, anti-cancer, approval, approve, approved, Arena, Arena Pharmaceuticals, Arena Pharmaceuticals Inc., ARNA, ASCO, assets, austerity, Avengers, BAC, Bank of America, Bank of America Corp., Bank of America Corporation, banks, bears, Benlysta, BID, big banks, Biopharmaceuticals, biotech, BofA, bulls, buyout, buyout bid, C, cancer, Carboxyl Terminal Peptide, catalyst, catalysts, Cel-Sci, CEL-SCI Corporation, CELH, Celsius Holdings, Celsius Holdings Inc., Citigroup, Citigroup Inc, Co.NYSE, Colombia, commercial, commercial launch, commercialization, companies, company, competition, conference, consumers, contract, control, Corp., Corporation, crisis, CTP, currency, CVM, D.C., Darryl Jones, deal, debt, debt crisis, decision, demand, development, diagnostic tests, diagnostics, diagnostics technology, DIS, distribution, Dollar, Dr. Darryl Jones, drachma, drug, Earnings, earnings announcement, Economic, economic recovery, economists, economy, elections, estimates, Euro, euro-zone, Europe, European, European debt, European debt crisis, European governments, European market, Facebook, Facebook IPO, FB, FCC, FDA, FDA advisory panel, FDA decision, Federal Communications Commission, fertility, financial, financials, France, French, future, GE, GE Security, generic, GlaxoSmithKline, GlaxoSmithKline plc, global, global sentiment, Government, government intervention, Greece, Greek, growth, GSK, HDF, HDF system, headlines, Hemodiafiltration, hGH-CTP, HGSI, higher stake, hiring, Holdings, hostile, Howard Stern, Human Genome Sciences, Implant Sciences, Implant Sciences Corporation, IMSC, Inc., industry, intellectual property, Intervention, investor interest, investors, IPO, J.C. Penney, J.C. Penney Company, J.C. Penney Company Inc., Japan, JCP, JP Morgan, JP Morgan Chase, JP Morgan Chase & Co., JPM, JWN, KERX, Keryx, Keryx Biopharmaceuticals, launch, leverage, Liberty, Liberty Media, Liberty Media Corporation, licenses, LMCA, LMCB, Lorcaserin, losses, lupus, lupus drug, M, Macy's Inc., Macys, major retailers, majority control, management, MannKind, Mannkind Corporation, Market, market cap, market share, markets, Marvel, media, Merck, Merck & Co., Merck & Co. Inc., Mets, miss, MNKD, MRK, NASDAQ, NASDAQ: SIRI, NASDAQ:AGEN, NASDAQ:ARNA, NASDAQ:FB, NASDAQ:HGSI, NASDAQ:KERX, NASDAQ:LMCA, NASDAQ:LMCB, NASDAQ:MNKD, NASDAQ:SGYP, NASDAQ:SIRI, NASDAQ:VVUS, NEPH, Nephros, Nephros Inc., New York, New York Mets, news, Nordstrom, Nordstrom Inc., NY Mets, NYSE, NYSE:BAC, NYSE:C, NYSE:DIS, NYSE:GSK, NYSE:JCP, NYSE:JPM, NYSE:JWN, NYSE:M, NYSE:MRK, NYSE:SKS, NYSE:TGT, NYSEAMEX, NYSEAMEX:CVM, NYSEAMEX:PBTH, offering, open market, operating licenses, opportunity, OTC, OTC:ACTC, OTC:NEPH, OTC:TTNP, partner, patent, patents, PBTH, Perifisone, Pharmaceuticals, phase III, Phase III results, Pink, PINK:ASCO, PINK:CELH, PINK:IMSC, PINK:TROV, pipeline, plan, plc, potential, PR firm, presentation, press release, private, private sector, product, products, profile, Prolor, Prolor Biotech, radio, recommended approval, recovery, regulators, report, reports, reputation, results, Retail, retailers, rights, safety, safety profile, Safran, Saks, Saks Inc., sales, sales growth, SandLs/Savings Banks, Satellite Radio, Secret Service, sector, security, security plan, sentiment, SGYP, share price, shareholders, shares, SIRI, Sirius, Sirius Radio, Sirius XM Radio, SiriusXM Radio, SKS, spending, stake, stem cell technology, stem-cell, stock, stock offering, stock to watch, stock watch, stocks, Summit of the Americas, Synergy Pharmaceuticals, Synergy Pharmaceuticals Inc., takeover, Target, Target Corporation, technology, TGT, The Walt Disney Company, Titan Pharmaceuticals, Titan Pharmaceuticals Inc., trading, trading action, trading losses, treatment, treatments, trial, trial catalysts, trial news, trial results, TROV, TrovaGene, TrovaGene Inc., TTNP, U.S., U.S. Federal Communications Commission, uncertainty, United States, valuation, Vivus, Vivus Inc., volatile, volatility, volume, VVUC, VVUS, Walt Disney, Walt Disney Company, Washington, Washington D.C., water purification, water purification products, Weekly Stock Watch, weight loss, weight loss drug, XM, XM Radio, Zerenex, Zerenex results

Market Watch: The Best Reason for Optimism is Pessimism

No Comments

Posted 13 May 2012 — by Covestor
Category Economy, Investing, Market News, Stocks, Trading

By Michael Tarsala

There’s a whole lot of pessimism about the stock market right now.

I hear it in hallway conversations and read about it in the media. There are people out there looking for the next big short strategy, trying to pretend they are the next John Paulson.

It goes beyond my anedcotes, though. Here are some data points:

Bullish sentiment is at an 8-month low, at about 25%, according to AAII. You would expect far more than 50% bullishness at an extreme. Read More

To discuss this article or any stock, please visit The Playground Discussion Forum!

Tags: AAII, bullish, bullish sentiment, bullishness, Covestor, data, decline, Greece, Hulbert, Hulbert Financial, Hulbert Financial Digest, John Paulson, JP Morgan, Market, market decline, market sentiment, markets, media, Michael Tarsala, optimism, pessimism, S&P, S&P 500, sentiment, short, Short Interest, stock market, stocks, Strategy, support, trading loss, worry

In Search of the Pinnacle Cancer Therapy: Redefining the World of Oncology

No Comments

Posted 10 May 2012 — by The Swiss Trader
Category AGEN, Biotechnology and Drugs, DNDN, Healthcare, IMUC, Investing, Market News, Sectors, Stocks, Trading

By The Swiss Trader

In the world of biotech, there is the quest for the cancer cure and companies will do whatever it takes to reach that goal. Just like the Fellowship had a long journey to Mordor, the journey to reaching a cancer cure is long and requires persistence and steadfast motivation. One major motivator, which exists with companies in the industry is not only developing their own products, but also acquiring other companies in order to combine their respective powers, so to speak, for this quest. Companies will spend in the billons to acquire promising new property even though there is always risk with mergers and acquisitions. The mega-biotech corporation, Amgen, Inc. (NASDAQ:AMGN), allegedly paid a combined $2.6 billion for BioVex and Micromet in 2011 for their very promising cancer treatments.

BioVex has a vaccine for the treatment of melanoma, head, and neck cancer, called OncoVex; Micromet has a drug to combat leukemia, lung, and gastrointestinal cancers, called blinatumomab (Bmab). Both are currently in Phase II testing and both treatments are immune-based cancer therapies. Read More

To discuss this article or any stock, please visit The Playground Discussion Forum!

Tags: acquire, acquisitions, AMEX, Amgen, Amgen Inc., AMGN, analyst, and neck cancer, antigens, biotech, BioTech Analyst, biotech companies, biotechnology, BioVex, blinatumomab, Bmab, cancer, cancer antigens, cancer cure, cancer stem cells, cancer therapies, cancer therapy, cancer treatments, cancer vaccine, cancer vaccines, cancers, Carol Werther, Clinical, Clinical Data, companies, company, Corporation, COST, cure, cure cancer, data, Dendreon, Dendreon Corporation, DNDN, drug, drugs, efficiency, evidence, glioblastoma multiforme, head, ICT-107, immune-based cancer therapies, ImmunoCellular, immunotherapies, immunotherapy, IMUC, Inc., industry, intellectual property, investors, Johns Hopkin, leukemia, Ltd., melanoma, Mergers, Mergers and Acquisitions, Micromet, mmunoCellular Therapeutics, mmunoCellular Therapeutics Ltd., mutual fund, NASDAQ, NASDAQ:AMGN, NASDAQ:DNDN, oncology, OncoVex, OTC, OTC:IMUC, ovarian cancer, Phase I, Phase I trial, phase II, Phase II trial, polyvalent vaccine, press release, products, prostate, prostate cancer vaccine, Provenge, results, risk, scale, scientists, stem cells, Strategy, study, Summer Street Partners, technology, testing, The Swiss Trader, therapy, treatments, trial, trials, University of Pennsylvania, University of Pittsburgh, vaccine, vaccine technology, vaccines

The Grumpy Old Accountants

No Comments

Posted 10 May 2012 — by Covestor
Category CHK, GRPN, Investing, Market News, Stocks, Trading

By Michael Tarsala

If you don’t know them already, allow me to introduce you to the Grumpy Old Accountants.

Two accounting professors — Anthony Catanach Jr. at Villanova, and J. Edward Ketz at Penn State — have been running a blog by that name for about a year now.

Keep it on your reading list.

These old dudes will teach you a thing or three about financial reporting. They’ll make you a smarter investor. And they’ll point out red flags as they see them, no holds barred.

In just the past year, Catanach and Ketz have filed two whistleblower complaints to the SEC. They were early critics of Groupon’s (NASDAQ:GRPN) books, ahead of its IPO. They’ve raised concerns about Chesapeake Energy Corporation (NYSE:CHK), and more than a dozen other companies.

Plus, they are taking on the Big 4 when it comes to the quality of company audits. Read More

Tags: accountants, accounting, accounting professor, accounting professors, Anthony Catanach Jr., audit, audits, blog, books, Chesapeake Energy, Chesapeake Energy Corporation, CHK, companies, company, company audits, complaints, concerns, Corporation, financial, financial reporting, Groupon, Groupon Inc., GRPN, grumpy, Grumpy Old Accountants, investor, IPO, J. Edward Ketz, legal, legal threats, Market, Michael Tarsala, money, NASDAQ, NASDAQ:GRPN, NYSE, NYSE:CHK, Penn State, Professor, professors, red flags, reporting, research, SEC, shorting, shorting the market, stock, stocks, The Grumpy Old Accountants, threats, Villanova, whistleblower, whistleblower complaints

Market Playground

Archive for the ‘Stocks’ Category

John Hussman: The Market’s ‘Dancing on the Edge of a Cliff’

Why We Changed the Lineup on Our ETF Models

TomTom (AMS:TOM2) Now Offering Free Roadside Assistance

How to Play the Indian Growth Story: INFY, HDB, RDY

JPMorgan Chase (NYSE:JPM) Shows Why Volcker Rule Has No Teeth

Market Watch: The Best Reason for Optimism is Pessimism

In Search of the Pinnacle Cancer Therapy: Redefining the World of Oncology

The Grumpy Old Accountants

Playground Radio Schedule

Satellite Radio Playground News

Recent Comments

Site Navigation

Archives

More Market Playground News

Site Navigation

Satellite Radio Playground News